Sort   by:  
 Page size 
TranscriptomicsIntegrative epigenomic analysis of differential DNA methylation in bladder cancer
Background Urothelial carcinoma of the bladder (UC) is a common malignancy. Although extensive transcriptome analysis has provided insights into the gene expression patterns of this tumor type, the mechanistic underpinnings of differential methylation remain poorly understood. Multi-level genomic da...
ORGANISM(S): Homo sapiens 
2015-05-28 | E-GEOD-58256 | biostudies-arrayexpress
TranscriptomicsDetailed analysis of 6p and 1q amplifications in urothelial carcinoma reveals SOX4 as an auxiliary target on 6p, and BCL9, CHDL1, MCL1, SETDB1, and HIF1B as putative targets on 1q.
Background: Previous array CGH analyses have revealed several recurring genomic alterations in urothelial carcinoma. The most common genomic amplifications occur at 6p22 and 1q21-24. The main target gene at 6p22 is believed to be E2F3. This gene is frequently co-amplified with CDKAL1 and SOX4 and th...
ORGANISM(S): Homo sapiens 
2013-08-30 | E-GEOD-40938 | biostudies-arrayexpress
Genomicsena-DATASET-GNE-27-07-2018-23:28:18:139-1120 - samples
Tumor DNA was extracted from formalin-fixed and paraffin embedded tumors of a large cohort of bladder cancer patients before treatment with anti-PD-L1. Normal DNA was extracted from matched PBMCs. Whole exome sequencing was performed. This is a subset of patients for which RNA sequencing is also pro...
EGAD00001004218 | EGA
Genomicsena-DATASET-GNE-22-02-2018-22:43:32:906-1098 - samples
RNA was extracted from formalin-fixed and paraffin embedded tumors of a large cohort of bladder cancer patients before treatment with anti-PD-L1. RNA was sequenced using a capture based approach (exome capture, RNA access).
EGAD00001003977 | EGA
GenomicsTGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
We examined tumours from a large cohort of patients with metastatic urothelial bladder cancer (mUC) treated with an anti–PD-L1 agent (atezolizumab) and identified major determinants of clinical response and immune escape. Whole transcriptome profiles were generated for 368 patients using TruSeq RNA ...
EGAS00001002556 | EGA
GenomicsData access committee handling data access requests for biomarker data from the clinical trial IMvigor210.
Data Access Committee EGAC00001000945
EGAC00001000945 | EGA
Sort   by:  
 Page size